$776 Million is the total value of Vivo Capital, LLC's 40 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 23.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Ascendis Pharmaadr | $144,138,000 | +1.7% | 2,166,832 | 0.0% | 18.57% | -7.5% | |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd | $80,998,000 | +53.4% | 2,049,545 | 0.0% | 10.44% | +39.6% | |
| KDMN | Buy | Kadmon Holdings (KDMN) | $68,919,000 | +386.5% | 10,454,545 | +213.6% | 8.88% | +342.5% |
| CDXS | Codexis, Inc. | $43,989,000 | +30.9% | 3,054,825 | 0.0% | 5.67% | +19.1% | |
| ACRS | Aclaris Therapeutics | $32,895,000 | +14.0% | 1,647,214 | 0.0% | 4.24% | +3.7% | |
| MNLO | Menlo Therapeutics | $32,571,000 | -78.4% | 4,011,236 | 0.0% | 4.20% | -80.3% | |
| APLS | Sell | Apellis Pharmaceuticals, Inc. | $32,043,000 | -0.6% | 1,456,499 | -0.1% | 4.13% | -9.6% |
| TCDA | New | Tricida, Inc. | $29,652,000 | – | 991,711 | +100.0% | 3.82% | – |
| FIXX | Buy | Homology Medicines, Inc. | $28,759,000 | +32.6% | 1,409,742 | +21.6% | 3.71% | +20.6% |
| MEIP | New | MEI Pharma Inc (NAS) | $26,007,000 | – | 6,600,660 | +100.0% | 3.35% | – |
| ARWR | Arrowhead Pharmaceuticals In | $25,840,000 | +88.6% | 1,900,000 | 0.0% | 3.33% | +71.6% | |
| EIGR | Eiger BioPharmaceuticals | $21,853,000 | +23.9% | 1,791,257 | 0.0% | 2.82% | +12.7% | |
| AMRS | Amyris, Inc. | $18,063,000 | -4.5% | 2,826,711 | 0.0% | 2.33% | -13.1% | |
| MDGL | Buy | Madrigal Pharmaceuticals Inc | $17,402,000 | +447.4% | 62,220 | +128.6% | 2.24% | +398.2% |
| KALA | Kala Pharmaceuticals, Inc. | $14,321,000 | -13.3% | 1,043,020 | 0.0% | 1.84% | -21.1% | |
| Nabriva Therapeutics Plc | $14,178,000 | -30.8% | 4,074,190 | 0.0% | 1.83% | -37.1% | ||
| OBSV | New | Obseva SA | $14,005,000 | – | 925,000 | +100.0% | 1.80% | – |
| CBAY | Buy | Cymabay Therapeutics inc | $12,158,000 | +17.0% | 906,000 | +13.2% | 1.57% | +6.5% |
| SBBP | Strongbridge Biopharma plc | $11,509,000 | -32.2% | 1,918,132 | 0.0% | 1.48% | -38.3% | |
| SELB | Sell | Selecta Biosciences, Inc. | $10,343,000 | -9.3% | 780,601 | -30.3% | 1.33% | -17.5% |
| SLNO | Buy | Soleno Therapeutics, Inc. | $10,202,000 | +39.5% | 4,359,683 | +8.1% | 1.32% | +26.9% |
| DCPH | New | Deciphera Pharmaceuticals In | $9,953,000 | – | 252,942 | +100.0% | 1.28% | – |
| GLMD | New | Galmed Pharmaceuticals Ltd | $9,433,000 | – | 792,707 | +100.0% | 1.22% | – |
| ZYME | New | Zymeworks Inc | $9,166,000 | – | 620,134 | +100.0% | 1.18% | – |
| SRRA | Sierra Oncology, Inc | $7,217,000 | +43.0% | 2,438,270 | 0.0% | 0.93% | +30.1% | |
| GNCA | Genocea Biosciences Inc(NMS) | $7,000,000 | -18.5% | 8,180,000 | 0.0% | 0.90% | -25.9% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $6,831,000 | +8.5% | 1,213,290 | 0.0% | 0.88% | -1.3% | |
| RGNX | Sell | Regenxbio Inc. | $5,912,000 | +20.5% | 82,403 | -49.9% | 0.76% | +9.6% |
| ZLAB | Sell | Zai Lab LTDadr | $5,371,000 | -11.4% | 231,010 | -18.6% | 0.69% | -19.3% |
| ZGNX | Zogenix, Inc. | $4,641,000 | +10.4% | 105,000 | 0.0% | 0.60% | +0.3% | |
| FOMX | Foamix Pharmaceuticals Ltd. | $4,284,000 | -2.3% | 855,000 | 0.0% | 0.55% | -11.1% | |
| BPMX | BioPharmX Corporation | $3,561,000 | -4.4% | 16,128,515 | 0.0% | 0.46% | -13.1% | |
| KNSA | New | Kiniksa Pharmaceuticals-A | $3,228,000 | – | 186,073 | +100.0% | 0.42% | – |
| VRNA | Verona Pharma Plcads | $2,792,000 | -90.6% | 1,492,951 | 0.0% | 0.36% | -91.5% | |
| TRVN | Trevena, Inc. | $2,488,000 | -12.2% | 1,728,000 | 0.0% | 0.32% | -20.0% | |
| KALV | KalVista Pharmaceuticals, Inc. | $2,439,000 | -14.3% | 300,325 | 0.0% | 0.31% | -22.1% | |
| AGRX | Agile Therapeutics, Inc. | $742,000 | -80.9% | 1,513,975 | 0.0% | 0.10% | -82.6% | |
| AKTX | Akari Therapeutics Plcadr | $674,000 | +7.2% | 345,850 | 0.0% | 0.09% | -2.2% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $414,000 | -22.2% | 195,474 | 0.0% | 0.05% | -29.3% | |
| SLNOW | Soleno Therapeutics, Inc.warrant | $79,000 | +243.5% | 188,772 | 0.0% | 0.01% | +233.3% | |
| AIMT | Exit | Aimmune Therapeutics, Inc. | $0 | – | -306,872 | -100.0% | -1.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.